Venker Eric

Eric Venker serves as the President and CEO of Immunovant, a subsidiary of Roivant Sciences Ltd., which focuses on innovative therapies in the healthcare sector. His recent insider trading activity, as disclosed in SEC Form 4 filings, shows a pattern of sale activity between November 24, 2025, and January 14, 2026, with a total of four reported sales. The largest disclosed transaction involved a sale of approximately $4.5 million in Roivant Sciences Ltd. (ROIV) shares on December 29, 2025.